Biodesix, Inc.
BDSX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.00 | -0.06 | 0.48 |
| FCF Yield | -15.77% | -16.00% | -9.54% | -2.22% |
| EV / EBITDA | -20.02 | -11.37 | -17.01 | -50.98 |
| Quality | ||||
| ROIC | -9.80% | -13.16% | -12.34% | -7.77% |
| Gross Margin | 81.14% | 79.86% | 79.38% | 78.75% |
| Cash Conversion Ratio | 1.02 | 0.57 | 0.77 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.12% | 22.50% | 22.29% | 23.12% |
| Free Cash Flow Growth | -34.87% | 24.26% | -75.48% | 54.55% |
| Safety | ||||
| Net Debt / EBITDA | -9.97 | -6.30 | -5.58 | -7.00 |
| Interest Coverage | -3.40 | -5.12 | -5.42 | -3.80 |
| Efficiency | ||||
| Inventory Turnover | 2.93 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3.81 | -32.88 | -32.81 | -7.58 |